For decades, aspirin has stood as the quiet sentinel against arterial clots in millions of hearts — affordable, familiar, imperfect. A research team in South India has now asked whether a second drug, clopidogrel, might offer better protection to a population whose genetic inheritance and vascular patterns set them apart from the Western patients on whom most evidence was built. Their findings, drawn from 84 patients over nine months, suggest a meaningful difference in outcomes — but the study's design leaves the question open, pointing not toward a conclusion, but toward the harder work still